Based on these results, on 11 December 2015, the FDA approved alectinib to treat patients with advanced ALK-positive NSCLC, whose disease has worsened after, or who could not tolerate treatment with crizotinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.